Clinical TrialJul 21, 2026, 06:11 AM
Innate Pharma Completes IPH4502 Phase 1 Enrollment; Positive Early Data
AI Summary
Innate Pharma SA announced the completion of enrollment in the dose escalation part of its Phase 1 study for IPH4502, a novel Nectin-4 exatecan ADC. Preliminary data from 76 patients are anticipated by year-end 2026. The study has shown a favorable safety profile with limited hematological toxicity and observed objective responses in heavily pre-treated patients with urothelial carcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma.
Key Highlights
- Enrollment completed in the Phase 1 dose escalation study of IPH4502.
- Preliminary data from 76 patients expected by year-end 2026.
- Favorable safety profile observed to date with limited hematological toxicity.
- Objective responses seen in heavily pre-treated patients with UC, NSCLC, and HNSCC.
- IPH4502 is Innate Pharma's proprietary Nectin-4 exatecan antibody-drug conjugate (ADC).
Price Impact
More from IPHA